Marcus Q Bernardini

Dr. Marcus Q Bernardini


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
AOAndreas Obermair
Andreas Obermair
RARebecca Asher
Rebecca Asher
RPRene Pareja
Rene Pareja
MFMichael Frumovitz
Michael Frumovitz
ALAldo Lopez
Aldo Lopez
PRPedro T. Ramirez
Pedro T. Ramirez

9 October 2020 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
MGMeinusha Govindarajan
Meinusha Govindarajan
CWChristoph Wohlmuth
Christoph Wohlmuth
MWMatthew Waas
Matthew Waas
MBMarcus Q Bernardini
Marcus Q Bernardini
TKThomas Kislinger
Thomas Kislinger
High-grade serous carcinoma (HGSC) is the most prevalent and aggressive subtype of ovarian cancer. The large degree of clinical heterogeneity within HGSC has justified deviations from the traditional one-size-fits-all clinical management approach. However, the majority of HGSC patients still relapse with chemo-resistant cancer and eventually succumb to their disease, evidence that further work is needed to improve patient outcomes. Advancements in high-throughput technologies have enabled novel insights into biological complexity, offering a large potential for informing precision medicine efforts. Here, we review the current landscape of clinical management for HGSC and highlight applications of high-throughput biological approaches for molecular subtyping and the discovery of putative blood-based biomarkers and novel therapeutic targets. Additionally, we present recent improvements in model systems and discuss how their intersection with high-throughput platforms and technological advancements is positioned to accelerate the realization of precision medicine in HGSC.

1 November 2015 in Gynecologic Oncology
Verified
Journal Article
Closed access
AAAlon D Altman
Alon D Altman
SFSarah E. Ferguson
Sarah E. Ferguson
EAEshetu G. Atenafu
Eshetu G. Atenafu
MKMartin Köbel
Martin Köbel
JMJessica N. McAlpine
Jessica N. McAlpine
MBMarcus Q Bernardini
Marcus Q Bernardini

31 January 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
CMCristina Mitric
Cristina Mitric
MBMarcus Q Bernardini
Marcus Q Bernardini
Endometrial carcinoma (EC) is traditionally treated with surgery and adjuvant treatment depending on clinicopathological risk factors. The genomic analysis of EC in 2013 and subsequent studies using immunohistochemistry have led to the current EC molecular classification into: polymerase epsilon mutated (POLEmut), p53 abnormal (p53abn), mismatch repair deficient (MMRd), and no specific molecular profile (NSMP). The four groups have prognostic value and represent a promising tool for clinical decision-making regarding adjuvant treatment. Molecular classification was integrated into the recent European Society of Gynecologic Oncology (ESGO) management guidelines. POLEmut EC has favorable outcomes and retrospective studies found that omitting adjuvant treatment is safe in this group; two prospective clinical trials, PORTEC-4 and TAPER, are ongoing to assess this. p53 abn is associated with increased recurrence, decreased survival, and benefitted from chemotherapy in the PORTEC-3 subgroup molecular analysis. The clinical trials PORTEC-4a and CANSTAMP will prospectively assess this. MMRd and NSMP groups have intermediate prognosis and will likely continue to rely closely on clinicopathological features for adjuvant treatment decisions. In addition, the molecular classification has led to exploring novel treatments such as checkpoint inhibitors. Overall, the molecular perspective on EC and associated clinical trials will likely refine EC risk stratification to optimize care and avoid overtreatment.

1 October 2017 in European Journal of Cancer
Verified
Journal Article
Closed access
YLY.C. Lee
Y.C. Lee
RMRoger L Milne
Roger L Milne
SLS. Lheureux
S. Lheureux
MFM. Friedlander
M. Friedlander
SMS.A. McLachlan
S.A. McLachlan
KPK.A. Phillips
K.A. Phillips

1 April 2016 in Gynecologic Oncology
Verified
Journal Article
Closed access
MBMarcus Q Bernardini
Marcus Q Bernardini
LGLilian T. Gien
Lilian T. Gien
SLSusie Lau
Susie Lau
AAAlon D Altman
Alon D Altman
BGBlake Gilks
Blake Gilks
JMJessica N. McAlpine
Jessica N. McAlpine